For healthcare professionals only
Promotional information from Lilly
BID: twice daily; LS: least-squares; SE: standard error
†p<0.001 for superiority vs active comparator.
‡p<0.0001 for noninferiority vs active comparator.
§p<0.001 for superiority vs placebo.
‖p<0.001 vs placebo.
No direct comparison can be made across clinical trials. All n values refer to intent-to-treat population.
In AWARD-1, AWARD-2 and AWARD-5, additional groups received Trulicity 0.75 mg, which is the recommended dose for monotherapy. For potentially vulnerable populations, 0.75 mg once-weekly can be considered as a starting dose.1
BID: twice daily; LS: least-squares; SE: standard error
†p<0.001 vs active comparator.
‡p<0.05 vs active comparator.
§p<0.001 vs placebo.
No direct comparisons can be made between clinical trials.
In AWARD-1, AWARD-2 and AWARD-5, additional groups received Trulicity 0.75mg, which is the recommended dose for monotherapy. For potentially vulnerable populations 0.75 mg once-weekly can be considered as a starting dose.
Trulicity 1.5 mg weekly was compared with placebo, both on a background of standard of care. The primary endpoint was 3-component MACE (time to first occurrence of non-fatal MI, non-fatal stroke, CV death).
Median Follow-up time – 5.4 years.
†CV disease: (MI, ischaemic stroke, unstable angina with ECG changes, myocardial ischaemia on imaging or stress test, or coronary, carotid, or peripheral revascularisation)
ADA: American Diabetes Association; ARR: absolute risk reduction; ASCVD: atherosclerotic cardiovascular disease; CI: confidence interval; CV: cardiovascular; ECG: electrocardiogram; HR: hazard ratio; MACE: major adverse cardiovascular events; MI: myocardial infarction
Significant updates relating to GLP-1 receptor agonists
Trulicity is not indicated for weight loss, and weight loss was a secondary endpoint in clinical trials.1
Trulicity has a side effect profile consistent with other GLP-1 receptor agonists.
Selected adverse events and precautions for use
For full information on adverse events and adverse event reporting, please see the prescribing information.
PP-DG-GB-1042 December 2021.
Trulicity® and Lilly are registered trademarks of Eli Lilly and Company.
© 2021 Eli Lilly and Company. All rights reserved.
Promotional information from Lilly
Trulicity® (dulaglutide) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when
metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.1
A Practical Guide intended for Healthcare Professionals to support starting your patient on Trulicity. It provides information such as indication, dosing, storage, disposal and information on the pen device.
A Patient Brochure intended for patients once they have been prescribed Trulicity. It provides information including how to take their medication, how it works and what they should do if they miss a dose
Trulicity Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3634/smpc .
PP-DG-GB-1042 December 2021.
Trulicity® and Lilly are registered trademarks of Eli Lilly and Company.
© 2021 Eli Lilly and Company. All rights reserved.
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2021 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
